Friday, April 28, 2017

Clinical Supplies Management Acquires Two European Companies

A private equity investor based in Greenwich, Connecticut, Great Point Partners has invested into more than 100 businesses in the public and private healthcare sector since 2003. Through December 2016 and January 2017, the private equity portfolio company Clinical Supplies Management (CSM) completed the acquisition of two companies that will expand its range of services in Europe.

Theorem Clinical Supply (TCS) was the first of these acquisitions. A Frankfurt-based company that offers clinical trial drug labeling, storage, packaging, and distribution, TCS’ services extend throughout Western Europe. The acquisition, which it completed in December 2016, enables CSM to provide significantly improved services to its global clients.

The TCS acquisition was complemented by the acquisition of Brussel’s B&C Group in January 2017. B&C provides a range of clinical trial supplies, in addition to biomedical sample services, via its custom system architecture, which CSM aims to leverage to serve the needs of its pharmaceutical clients in both Europe and the United States.

Tuesday, April 18, 2017

Great Point Partners’ Sale of Equian

Maintaining an investment portfolio with portfolio companies primarily domiciled in the United States, Greenwich, Connecticut investment firm Great Point Partners (GPP) focuses primarily on health care companies. Among the firms Great Point Partners has invested in is Equian, which it sold in December 2015 to New Mountain Capital, LLC.

A leading payment integrity solutions provider that offers services to medical claims payers, Equian became a Great Point Partner's portfolio company in 2007. In the eight years that Great Point Partner's and Equian worked together, Equian achieved and exceeded the market positioning and corporate growth goals that its co-founders John Ansay and Russ Sherlock set for the firm.

In speaking about the sale that was achieved in December 2015 to New Mountain Capital, Great Point Partners’s principal Noah F. Rhodes III noted during GPP's investment period Equian had 11 add-on acquisitions and a strong annual earnings growth rate.